Obesity-driven inflammation and colorectal cancer

Current Medicinal Chemistry

Volumn 19, Issue 34, 2012, Pages 5837-5853

  Vazzana, N ^a   Riondino, S ^b   Toto, V ^a   Guadagni, F ^b   Roselli, M ^c   Davi G ^a   Ferroni, P ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Adipokines; Colorectal cancer; Free fatty acid; Gut microbiota; Inflammation; Insulin resistance; Liver inflammation; Non alcoholic steatohepatitis; Visceral obesity; White adipose tissue

Indexed keywords

ACETYLSALICYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; CYTOKINE; GHRELIN; HYPOXIA INDUCIBLE FACTOR 1; I KAPPA B ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; RESISTIN; SOMATOMEDIN C; STAT3 PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; COLORECTAL CANCER; COLORECTAL CARCINOGENESIS; CYTOKINE RELEASE; DIETARY INTAKE; DISEASE FREE SURVIVAL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; NONHUMAN; OBESITY; OVERALL SURVIVAL; PHYSICAL ACTIVITY; POSITIVE FEEDBACK; REVIEW; WEIGHT REDUCTION;

ADIPOKINES; COLORECTAL NEOPLASMS; CYTOKINES; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; OBESITY; VASCULAR DISEASES;

EID: 84871279679     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804143349     Document Type: Review

References (284)

1. Binkin, N.; Fontana, G.; Lamberti, A.; Cattaneo, C.; Baglio, G.; Perra, A.; Spinelli, A. A national survey of the prevalence of childhood overweight and obesity in Italy. Obes. Rev., 2010, 11, 2-10.
2. Baskin, M. L.; Ard, J.; Franklin, F.; Allison, D. B. Prevalence of obesity in the United States. Obes. Rev., 2005, 6, 5-7.
3. World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ. Tech. Rep. Ser., 1995, 854, 427-437.
4. Billon, N.; Dani, C.; Developmental Origins of the Adipocyte Lineage: New Insights from Genetics and Genomics Studies. Stem Cell Rev., 2012, 8, 55-66.
5. Nedergaard, J.; Bengtsson, T.; Cannon, B. Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab., 2007, 293, E444-452.
6. Virtanen, K. A.; Lidell, M. E.; Orava, J.; Heglind, M.; Westergren, R.; Niemi, T.; Taittonen, M.; Laine, J.; Savisto, N. J.; Enerbäck, S.; Nuutila, P. Functional brown adipose tissue in healthy adults. N. Engl. J. Med., 2009, 360, 1518-1525.
7. Cypess, A. M.; Lehman, S.; Williams, G.; Tal, I.; Rodman, D.; Goldfine, A. B.; Kuo, F. C.; Palmer, E. L.; Tseng, Y. H.; Doria, A.; Kolodny, G. M.; Kahn, C. R. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med., 2009, 360, 1509-1517.
8. Gesta, S.; Tseng, Y. H.; Kahn, C. R. Developmental origin of fat: tracking obesity to its source. Cell, 2008, 131, 242-256.
9. Kant, P.; Hull, M. A. Excess body weight and obesity-the link with gastrointestinal and hepatobiliary cancer. Nat. Rev. Gastroenterol. Hepatol., 2011, 8, 224-238.
10. Morris, J. N. Occupation and coronary heart disease. Arch. Intern. Med., 1959, 104, 903-907.
11. Vague, J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout and uric-calculous disease. Am. J. Clin. Nutr., 1956, 4, 20-34.
12. Price, G. M.; Uauy, R.; Breeze, E.; Bulpitt, C. J.; Fletcher, A. E. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. Am. J. Clin. Nutr., 2006, 84, 449-460.
13. de Koning, L.; Merchant, A. T.; Pogue, J.; Anand, SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur. Heart. J., 2007, 28, 850-856.
14. Guh, D. P.; Zhang, W.; Bansback, N.; Amarsi, Z.; Birmingham, C. L.; Anis, A. H. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health, 2009, 25, 9-88.
15. Strazzullo, P.; D'Elia, L.; Cairella, G.; Garbagnati, F.; Cappuccio, F. P.; Scalfi, L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke, 2010, 41, 418-26.
16. Gunter, M. J.; Leitzmann, M. F. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J. Nutr. Biochem., 2006, 17, 145-156.
17. Larsson, S. C.; Wolk, A. Obesity and colon and rectal cancer risk: a metaanalysis of prospective studies. Am. J. Clin. Nutr., 2007, 86, 556-565.
18. Moghaddam, A. A.; Woodward, M.; Huxley, R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70, 000 events. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 2533-2547.
19. Dai, Z.; Xu, Y. C.; Niu, L. Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J. Gastroenterol., 2007, 13, 4199-4206.
20. Harriss, D. J.; Atkinson, G.; George, K.; Cable, N. T.; Reilly, T.; Haboubi, N.; Zwahlen, M.; Egger, M.; Renehan, A. G.; C-CLEAR group. Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. Colorectal Dis., 2009, 11, 547-563.
21. Ning, Y.; Wang, L.; Giovannucci, E. L. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes. Rev., 2010, 11, 19-30.
22. Kune, G. A.; Kune, S.; Watson, L. F. Body weight and physical activity as predictors of colorectal cancer risk. Nutr. Cancer, 1990, 13, 9-17.
23. Gerhardsson de Verdier, M.; Hagman, U.; Steineck, G.; Rieger, A.; Norell, S. E. Diet, body mass and colorectal cancer: a case-referent study in Stockholm. Int. J. Cancer, 1990, 46, 832-838.
24. Lee, I. M.; Paffenbarger, R. S. Jr. Quetelet's index and risk of colon cancer in college alumni. J. Natl. Cancer Inst., 1992, 84, 1326-1331.
25. Dietz, A. T.; Newcomb, P. A.; Marcus, P. M.; Storer, B. E. The association of body size and large bowel cancer risk in Wisconsin (United States) women. Cancer Causes Control, 1995, 6, 30-36.
26. Le Marchand, L.; Wilkens, L. R.; Kolonel, L. N.; Hankin, J. H.; Lyu, L. C. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res., 1997, 57, 4787-4794.
27. Martinez, M. E.; Giovannucci, E.; Spiegelman, D.; Hunter, D. J.; Willett, W. C.; Colditz, G. A. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J. Natl. Cancer Inst., 1997, 89, 948-955.
28. Caan, B. J.; Coates, A. O.; Slattery, M. L.; Potter, J. D.; Quesenberry, C. P. Jr; Edwards, S. M. Body size and the risk of colon cancer in a large case-control study. Int. J. Obes. Relat. Metab. Disord., 1998, 22, 178-184.
29. Russo, A.; Franceschi, S.; La Vecchia, C.; Dal Maso, L.; Montella, M.; Conti, E.; Giacosa, A.; Falcini, F.; Negri, E. Body size and colorectal-cancer risk. Int. J. Cancer, 1998, 78, 161-165.
30. Boutron-Ruault, M. C.; Senesse, P.; Meance, S.; Belghiti, C; Faivre, J. Energy intake, body mass index, physical activity, and the colorectal adenomacarcinoma sequence. Nutr. Cancer, 2001, 39, 50-57.
31. Lin, J.; Zhang, S. M.; Cook, N. R.; Rexrode, K. M.; Lee, I. M.; Buring, J. E. Body mass index and risk of colorectal cancer in women (United States). Cancer Causes Control, 2004, 15, 581-9.
32. Moore, L. L.; Bradlee, M. L.; Singer, M. R.; Splansky, G. L.; Proctor, M. H.; Ellison, R. C.; Kreger, B. E. BMI and waist circumference as predictors of lifetime colon cancer risk in Framingham Study adults. Int. J. Obes., 2004, 28, 559-567.
33. McTiernan, A. Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park), 2005, 19, 871-881.
34. Calle, E. E.; Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer, 2004, 4, 579-591.
35. Calle, E. E.; Rodriguez, C; Walker-Thurmond, K.; Thun, M. J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med., 2003, 348, 1625-638.
36. Doyle, S. L.; Donohoe, C. L.; Lysaght, J.; Reynolds, J. V. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc. Nutr. Soc, 2012, 71, 181-189.
37. Ikeoka, D.; Mader, J. K.; Pieber, T. R. Adipose tissue, inflammation and cardiovascular disease. Rev. Assoc. Med. Bras., 2010, 56, 116-121.
38. Vazzana, N.; Santilli, F.; Sestili, S.; Cuccurullo, C; Davi, G. Determinants of increased cardiovascular disease in obesity and metabolic syndrome. Curr. Med. Chem., 2011, 18, 5267-5280.
39. Park, H. S.; Park, J. Y.; Yu, R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-[alpha] and IL-6. Diab. Res. Clin. Pract, 2005 69, 29-35.
40. Engström, G.; Hedblad, B.; Stavenow, L.; Jonsson, S.; Lind, P.; Janzon, L.; Lindgärde, F. Incidence of obesity-associated cardiovascular disease is related to inflammation-sensitive plasma proteins: a population-based cohort study. Arterioscler. Thromb. Vasc. Biol, 2004, 24, 1498-1502.
41. Manigrasso, M. R.; Ferroni, P.; Santilli, F.; Taraborelli, T.; Guagnano, M. T.; Michetti, N.; Davì, G. Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss. J. Clin. Endocrinol. Metab., 2005, 90, 5876-5879.
42. Williams, L. M.; Ricchetti, G.; Sarma, U.; Smallie, T.; Foxwell, B. M. Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology, 2004, 113, 281-292.
43. Yudkin, J. S.; Kumari, M.; Humphries, S. E.; Mohamed-Ali, V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis, 2000, 148, 209-214.
44. Paz-Filho, G.; Lim, E. L.; Wong, M. L.; Licinio, J. Associations between adipokines and obesity-related cancer. Front. Biosci., 2011, 16, 1634-1650.
45. Dandona, P.; Aljada, A.; Chaudhuri, A.; Mohanty, P.; Garg, R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation, 2005, 111, 1448-1454.
46. Sandhu, M. S.; Dunger, D. B.; Giovannucci, E. L. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J. Natl. Cancer Inst., 2002, 94, 972-980.
47. Powell, E. E.; Jonsson, J. R.; Clouston, A. D. Steatosis: Co-factor in other liver diseases. Hepatology, 2005, 42, 5-13.
48. Siegel, A. B.; Zhu, A. X. Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link. Cancer, 2009, 115, 5651-5661.
49. Wong, V. W.; Wong, G. L.; Tsang, S. W.; Fan, T.; Chu, W. C.; Woo, J.; Chan, A. W.; Choi, P. C.; Chim, A. M.; Lau, J. Y; Chan, F. K.; Sung, J. J.; Chan, H. L. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut, 2011, 60, 829-836.
50. Shi, H.; Kokoeva, M. V.; Inouye, K.; Tzameli, I.; Yin, H.; Flier, J. S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest., 2006, 116, 3015-3025.
51. Kim, S. J.; Choi, Y.; Choi, Y. H.; Park, T. Obesity activates toll-like receptormediated proinflammatory signaling cascades in the adipose tissue of mice. J. Nutr. Biochem., 2012, 23, 113-122.
52. Könner, A. C.; Brüning, J. C. Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol. Metab., 2011, 22, 16-23.
53. Yehuda-Shnaidman, E.; Schwartz, B. Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. Obes. Rev., 2012, Sep. 3. [Epub ahead of print].
54. Cammarota, R.; Bertolini, V.; Pennesi, G.; Bucci, E. O.; Gottardi, O.; Garlanda, C; Laghi, L.; Barberis, M. C.; Sessa, F.; Noonan, D. M.; Albini, A. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J. Transl. Med., 2010, 8, 112.
55. Tilg, H. Obesity, metabolic syndrome, and microbiota: multiple interactions. J. Clin. Gastroenterol, 2010, 44, S16-18.
56. Vijay-Kumar, M.; Aitken, J. D.; Carvalho, F. A.; Cullender, T. C.; Mwangi, S.; Srinivasan, S.; Sitaraman, S. V.; Knight, R.; Ley, R. E.; Gewirtz, A. T. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science, 2010, 328, 228-231.
57. Carvalho, F. A.; Aitken, J. D.; Vijay-Kumar, M.; Gewirtz, A. T. Toll-like receptor-gut microbiota interactions: perturb at your own risk! Annu. Rev. Physiol, 2012, 74, 177-198.
58. Koyama, H.; Shoji, T.; Yokoyama, H.; Motoyama, K.; Mori, K.; Fukumoto, S.; Emoto, M.; Shoji, T.; Tamei, H.; Matsuki, H.; Sakurai, S.; Yamamoto, Y.; Yonekura, H.; Watanabe, T.; Yamamoto, H.; Nishizawa, Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2005, 25, 2587-2593.
59. Abe, R.; Yamagishi, S. AGE-RAGE system and carcinogenesis. Curr. Pharm. Des., 2008, 14, 940-945.
60. Heijmans, J.; Büller, N. V.; Hoff, E.; Dihal, A. A.; van der Poll, T.; van Zoelen, M. A.; Bierhaus, A.; Biemond, I.; Hardwick, J. C.; Hommes, D. W.; Muncan, V.; van den Brink, G. R. Rage signalling promotes intestinal tumourigenesis. Oncogene, 2012, Apr. 2. [Epub ahead of print].
61. Santilli, F.; Vazzana, N.; Bucciarelli, L. G.; Davì, G. Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr. Med. Chem., 2009, 16, 940-952.
62. Vazzana, N.; Santilli, F.; Cuccurullo, C.; Davì, G. Soluble forms of RAGE in internal medicine. Intern. Emerg. Med., 2009, 4, 389-401.
63. Davì, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med., 2007, 357, 2482-2494.
64. Davì, G.; Guagnano, M. T.; Ciabattoni, G.; Basili, S.; Falco, A.; Marinopiccoli, M.; Nutini, M.; Sensi, S.; Patrono, C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA, 2002, 288, 2008-2014.
65. Basili, S.; Pacini, G.; Guagnano, M. T.; Manigrasso, M. R.; Santilli, F.; Pettinella, C.; Ciabattoni, G.; Patrono, C.; Davì, G. Insulin resistance as a determinant of platelet activation in obese women. J. Am. Coll. Cardiol., 2006, 48, 2531-2538.
66. Santilli, F.; Vazzana, N.; Liani, R.; Guagnano, M. T.; Davì, G. Platelet activation in obesity and metabolic syndrome. Obes Rev., 2012, 13, 27-42.
67. Erpenbeck, L.; Schön, M. P. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood., 2010, 115, 3427-3436.
68. Bays, H. E.; González-Campoy, J. M.; Henry, R. R.; Bergman, D. A.; Kitabchi, A. E.; Schorr, A. B.; Rodbard, H. W.; Adiposopathy Working Group. Is adiposopathy (sick fat) an endocrine disease? Int. J. Clin. Pract., 2008, 62, 1474-1483.
69. Bays, H. Adiposopathy: role of adipocyte factors in a new paradigm. Expert Review of Cardiovascular Therapy, 2005, 3, 187-189.
70. Marques, B. G.; Hausman, D. B.; Martin, R. J. Association of fat cell size and paracrine growth factors in development of hyperplastic obesity. Am. J. Physiol., 1998, 275, 1898-1908.
71. Grundy, S. M. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab., 2004, 89, 2595-2600.
72. Smas, C. M.; Sul, H. S. Control of adipocyte differentiation. Biochemical Journal, 1995, 309, 697-710.
73. Rosen, E. D.; MacDougald, O. A. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol., 2006;7, 885-896.
74. Tchkonia, T.; Lenburg, M.; Thomou, T.; Giorgadze, N.; Frampton, G.; Pirtskhalava, T.; Cartwright, A.; Cartwright, M.; Flanagan, J.; Karagiannides, I.; Gerry, N.; Forse, R. A.; Tchoukalova, Y.; Jensen, M. D.; Pothoulakis, C.; Kirkland, J. L. Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am. J. Physiol. Endocrinol. Metab., 2007, 292, E298-307.
75. Vohl, M. C.; Sladek, R.; Robitaille, J.; Gurd, S.; Marceau, P.; Richard, D.; Hudson, T. J.; Tchernof, A. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes. Res., 2004, 12, 1217-1222.
76. Tchkonia, T.; Tchoukalova, Y. D.; Giorgadze, N.; Pirtskhalava, T.; Karagiannides, I.; Forse, R. A.; Koo, A.; Stevenson, M.; Chinnappan, D.; Cartwright, A.; Jensen, M. D.; Kirkland, J. L. Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E267-277.
77. Vodyanik, M. A.; Yu, J.; Zhang, X.; Tian, S.; Stewart, R.; Thomson, J. A.; Slukvin, I. I. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell., 2010, 7, 718-729.
78. Lee, G.; Kim, H.; Elkabetz, Y.; Al Shamy, G.; Panagiotakos, G.; Barberi, T.; Tabar, V.; Studer, L. Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells. Nat. Biotechnol., 2007, 25, 1468-1475.
79. Hotamisligil, G. S. Inflammatory pathways and insulin action. Int. J. Obes. Relat. Metab. Disord., 2003, 27, S53-S55.
80. Cousin, B.; Munoz, O.; Andre, M.; Fontanilles, A. M.; Dani, C.; Cousin, J. L.; Laharrague, P.; Casteilla, L.; Pénicaud, L. A role for preadipocytes as macrophage-like cells. FASEB J., 1999, 13, 305-312.
81. Xu, H.; Barnes, G. T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C. J.; Sole, J.; Nichols, A.; Ross, J. S.; Tartaglia, L. A.; Chen, H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest., 2003, 112, 1821-1830.
82. Weisberg, S. P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R. L.; Ferrante, A. W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 2003, 112, 1796-1808.
83. Schäffler, A.; Schölmerich, J.; Salzberger, B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol., 2007, 28, 393-399.
84. Lumeng, C. N.; Bodzin, J. L.; Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest., 2007, 117, 175-184.
85. Hao, N. B.; Lü, M. H.; Fan, Y. H.; Cao, Y. L.; Zhang, Z. R.; Yang, S. M. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol, 2012, 2012, 948098.
86. Kim, J. A.; Wei, Y.; Sowers, J. R. Role of mitochondrial dysfunction in insulin resistance. Circ. Res., 2008, 102, 401-414.
87. Boudina, S.; Sena, S.; O'Neill, B. T.; Tathireddy, P.; Young, M. E.; Abel, E. D. Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation., 2005, 112, 2686-2695.
88. de Ferranti, S.; Mozaffarian, D. The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. Clin. Chem., 2008, 54, 945-955.
89. Suganami, T.; Nishida, J.; Ogawa, Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor α. Arterioscler. Thromb. Vasc. Biol, 2005, 25, 2062-2068.
90. Huang, X. F.; Chen, J. Z. Obesity, the PI3K/Akt signal pathway and colon cancer. Obes. Rev., 2009, 10, 610-616.
91. Zick, Y. Role of Ser/Thr kinases in the uncoupling of insulin signaling. Int. J. Obes. Relat. Metab. Disord., 2003, 27, 56-60.
92. Shoelson, S. E.; Lee, J.; Yuan, M. Inflammation and the IKK beta/I kappa B/NFkappa B axis in obesity-and diet-induced resistance. Int. J. Obes. Relat. Metab. Disord., 2003, 27, 49-52.
93. Browlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414, 813-820.
94. Carswell, E. A.; Old, L. J.; Kassel, R. L.; Green, S.; Fiore, N; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 1975, 72, 3666-3670.
95. Lejeune, F. J.; Ruegg, C; Lienard, D. Clinical applications of TNF-αlpha in cancer. Curr. Opin. Immunol, 1998, 10, 573-580.
96. Kaiser, G. C.; Polk, D. B. Tumor necrosis factor alpha regulates proliferation in a mouse intestinal cell line. Gastroenterology, 1997, 112, 1231-1240.
97. Montesano, R.; Soulie, P. Eble, J. A.; Carrozzino, F. Tumour necrosis factor alpha confers an invasive, transformed phenotype on mammary epithelial cells. J. Cell. Sci., 2005, 118, 3487-3500.
98. Balkwill, F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev., 2002, 13, 135-141.
99. Liu, Z. G.; Hu, H.; Goeddel, D. V.; Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis, while NF-κB activation prevents cell death. Cell, 1996, 87, 565-576.
100. Beg, A. A.; Baltimore, D. An essential role for NF-κB in preventing TNF-α induced cell death. Science, 1996, 274, 782-784.
101. Van Antwerp, D. J.; Martin, SJ.; Kafri, T.; Green, D. R.; Verma, I. M. Suppression of TNFα-induced apoptosis by NF-κB. Science, 1996, 274, 787-789.
102. Wang, C. Y.; Mayo, M. W.; Baldwin, A. S. TNF-α and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science, 1996, 274, 784-787.
103. Karin, M. Nuclear factor-κB in cancer development and progression. Nature, 2006, 441, 431-436.
104. Read, M. A.; Whiteley, M. Z.; Williams, A. J.; Collins, T. NF-κB, and IκBcα. An inducible regulatory system in endothelial activation. J. Exp. Med., 1994, 179, 503-512.
105. Jain, S. S.; Ashok Kumar, M.; Bird, R. P. Differential expression of TNF-α signaling molecules and ERK1 in distal and proximal colonic tumors associated with obesity. Tumour Biol, 2011, 32, 1005-1012.
106. Liu, Z.; Brooks, R. S.; Ciappio, E. D.; Kim, S. J.; Crott, J. W.; Bennett, G.; Greenberg, A. S.; Mason, J. B. Diet-induced obesity elevates colonic TNF-α in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J. Nutr. Biochem., 2012, 23, 1207-1213.
107. Sarma, V.; Wolf, F. W.; Marks, R. M.; Shows, T. B.; Dixit, V. M. Cloning of a novel tumor necrosis factor-alpha-inducible primary response gene that is differentially expressed in development and capillary tube-like formation in vitro. J. Immunol, 1992, 148, 3302-3312.
108. Keffer, J.; Probert, L.; Cazlaris, H.; Georgopoulos, S.; Kaslaris, E.; Kioussis, D.; Kollias, G. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J., 1991, 10, 4025-4031.
109. Zhang, R.; Xu, Y.; Ekman, N; Wu, Z.; Wu, J.; Alitalo, K.; Min, W. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J. Biol. Chem. 2003, 278; 51267-51276.
110. Aggarwal, B. B.; Shishodia, S.; Sandur, S. K.; Pandey, M. K.; Sethi, G. Inflammation and cancer: How hot is the link? Biochem. Pharmacol. 2006, 72; 1605-1621.
111. Iruela-Arispe, M. L.; Dvorak, H. F. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb. Haemost, 1997, 78, 672-677.
112. Ristimaki, A.; Narko, K.; Enholm, B.; Joukov, V.; Alitalo, K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem., 1998, 273, 8413-8418.
113. Grivennikov, S.; Karin, E.; Terzic, J.; Mucida, D.; Yu, G. Y.; Vallabhapurapu, S.; Scheller, J.; Rose-John, S.; Cheroutre, H.; Eckmann, L.; Karin, M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 2009, 15, 103-113.
114. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer, 2009, 9, 798-809.
115. Grivennikov, S. I.; Greten. F. R.; Karin, M. Immunity, inflammation, and cancer. Cell, 2010, 140, 883-899.
116. Becker, C; Fantini, M. C.; Schramm, C; Lehr, H. A.; Wirtz, S.; Nikolaev, A.; Burg, J.; Strand, S.; Kiesslich, R.; Huber, S.; Ito, H.; Nishimoto, N; Yoshizaki, K.; Kishimoto, T; Galle, P. R.; Blessing, M.; Rose-John, S.; Neurath, M. F. TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 2004, 21, 491-501.
117. Neurath, M. F.; Finotto, S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev., 2011, 22, 83-89.
118. Iliopoulos, D.; Hirsch, H. A.; Struhl, K. An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation. Cell, 2009, 139, 693-706.
119. Zamarron, B. F.; Chen, W. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci., 2011, 7, 651-658.
120. Fan, Y; Ye, J.; Shen, F.; Zhu. Y; Yeghiazarians, Y; Zhu W.; Chen, Y; Lawton, M. T.; Young, W. L.; Yang, G. Y. Interleukin-6 stimulates circulating blood-derived endothelial progenitor cell angiogenesis in vitro. J. Cereb. Blood Flow. Metab., 2008, 28, 90-98.
121. Kujawski, M.; Kortylewski, M.; Lee, H.; Herrmann, A.; Kay, H.; Yu, H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest, 2008, 118, 3367-3377.
122. Wei, L. H.; Kuo, M. L.; Chen, C. A.; Chou, C. H.; Lai, K. B.; Lee, C. N.; Hsieh, C. Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene, 2003, 22, 1517-1527.
123. Dankbar, B.; Padro, T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, RM.; Serve, H.; Berdel, W. E.; Kienast, J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 2000, 95, 2630-2636.
124. Huang, S. P.; Wu, M. S.; Shun, C. T.; Wang, H. P.; Lin M. T.; Kuo, M. L.; Lin, J. T. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J. Biomed. Sci., 2004, 11, 517-527.
125. Kim, M. Y; Oskarsson, T; Acharyya, S.; Nguyen, D. X.; Zhang, X. H., Norton, L., Massaguè, J. Tumor self-seeding by circulating cancer cells. Cell, 2009, 139, 1315-1326.
126. Nakano, Y; Tobe, T.; Choi-Miura, N. H.; Mazda, T.; Tomita, M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem., 1996, 120, 803-812.
127. Hu, E.; Liang, P.; Spiegelman, B. M. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem., 1996, 271, 10697-10703.
128. Maeda, K.; Okubo, K.; Shimomura, I.; Funahashi, T; Matsuzawa, Y. and Matsubara, K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun., 1996, 221, 286-289.
129. Scherer, P. E.; Williams, S.; Fogliano, M.; Baldini, G.; Lodish, H. F.; A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem., 1995, 270, 26746-26749.
130. Kadowaki, T.; Yamauchi, T.; Kubota, N; Hara, K.; Ueki, K.; Tobe, K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest, 2006, 116; 1784-1792.
131. Nakashima, R.; Kamei, N.; Yamane, K.; Nakanishi, S.; Nakashima, A.; Kohno, N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J. Clin. Endocrinol. Metab. 2006, 91, 3873-3877.
132. Hanley, AJ.; Bowden, D.; Wagenknecht, L. E.; Balasubramanyam, A.; Langfeld, C; Saad, M. F.; Rotter, J. I.; Guo, X.; Chen, YD.; Bryer Ash, M.; Norris, J. M.; Haffner, S. M. Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J. Clin. Endocrinol. Metab., 2007, 92, 2665-2671.
133. Kelesidis, I.; Kelesidis, T.; Mantzoros, C. S. Adiponectin and cancer: a systematic review. Br. J. Cancer, 2006, 94; 1221-5122.
134. Gialamas, S. P.; Petridou, E. T.; Tseleni-Balafouta, S.; Spyridopoulos, T. N.; Matsoukis, I. L.; Kondi-Pafiti, A.; Zografos, G.; Mantzoros, C. S. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism. 2011, 60, 1530-1538.
135. Sugiyama, M.; Takahashi, H.; Hosono, K.; Endo, H.; Kato, S.; Yoneda, K.; Nozaki, Y; Fujita, K.; Yoneda, M.; Wada, K.; Nakagama, H.; Nakajima, A. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int. J. Oncol, 2009, 34, 339-344.
136. Habeeb, B. S.; Kitayama, J.; Nagawa, H. Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci., 2011, 102, 999-1006.
137. Otani, K.; Kitayama, J.; Yasuda, K.; Nio, Y; Iwabu, M.; Okudaira, S.; Aoki, J.; Yamauchi, T; Nakagawa, K. Adiponectin suppresses tumorigenesis in Apc (Min/+) mice. Cancer Lett, 2010, 288, 177-182.
138. Saxena, A.; Chumanevich, A.; Fletcher, E.; Larsen, B.; Lattwein, K.; Kaur, K.; Fayad, R. Adiponectin deficiency: Role in chronic inflammation induced colon cancer. Biochim. Biophys. Acta, 2012, 1822, 527-536.
139. Boddicker, R. L.; Whitley, E.; Birt, D. F.; Spurlock, M. E. Early lesion formation in colorectal carcinogenesis is associated with adiponectin status whereas neoplastic lesions are associated with diet and sex in C57BL/6J mice. Nutr. Cancer, 2011, 63, 1297-1306.
140. Byeon, J. S.; Jeong, J. Y.; Kim, M. J.; Lee, S. M.; Nam, W. H.; Myung, S. J.; Kim, J. G.; Yang, S. K.; Kim, J. H.; Suh, D. J. Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int. J. Cancer, 2010, 127, 2758-2767.
141. Bråkenhielm, E.; Veitonmäki, N; Cao, R.; Kihara, S.; Matsuzawa, Y.; Zhivotovsky, B.; Funahashi, T.; Cao, Y. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc. Natl. Acad. Sci. USA, 2004, 101, 2476-2481.
142. Adya, R.; Tan, B. K.; Chen, J.; Randeva, H. S. Protective Actions of Globular and Full-Length Adiponectin on Human Endothelial Cells: Novel Insights into Adiponectin-Induced Angiogenesis. J. Vasc. Res., 2012, 49, 534-543.
143. Koerner, A.; Kratzsch, J.; Kiess, W. Adipocytokines: leptin - the classical, resistin - the controversial, adiponectin - the promising, and more to come. Best Pract. Res. Clin. Endocrinol. Metab., 2005, 19, 525-546.
144. Zhang, Y; Proenca, R.; Maffei, M.; Barone, M.; Leopold, L.; Friedman, J. M. Positional cloning of the mouse obese gene and its human homologue. Nature, 1994, 372, 425-432.
145. Somasundar, P.; Riggs, D.; Jackson, B.; Vona-Davis, L.; Mcfadden, D. W. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am. J. Surg., 2003, 186, 575-578.
146. Lin, C; Pai, R.; Tran, T.; Tarnawsk I, A. Does leptin promote gastric cancer growth? Am. J. Gastroenterol, 2003, 98, 55-56.
147. Aparicio, T.; Kotelevets, L.; Tsocas, A.; Laigneau, JP.; Sobhani, I.; Chastre, E.; Lehy, T. Leptin stimulates the proliferation of human colon cancer cells in vitro but does not promote the growth of colon cancer xenografts in nude mice or intestinal tumorigenesis in Apc (Min/+) mice. Gut, 2005, 54, 1136-1145.
148. Hardwick, J. C.; Van Den Brink, G. R.; Offerhaus, G. J.; Van Deventer, SJ.; Peppelenbosch, M. P. Leptin is a growth factor for colonic epithelial cells. Gastroenterology, 2001, 121, 79-90.
149. Rouet-Benzineb, P.; Aparicio, T.; Guilmeau, S.; Pouzet, C; Descatoire, V; Buyse, M.; Bado, A. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-κB signaling. J. Biol. Chem., 2004, 279, 16495-16502.
150. Hoda, M. R.; Keely, S. J.; Bertelsen, L. S.; Junger, W. G.; Dharmasena, D.; Barrett, K. E. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br. J. Surg., 2007, 94, 346-354.
151. Amemori, S.; Ootani, A.; Aoki, S.; Fujise, T.; Shimoda, R.; Kakimoto, T.; Shiraishi, R.; Sakata, Y; Tsunada, S.; Iwakiri, R.; Fujimoto, K. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, 923-929.
152. Attoub, S.; Noe, V; Pirola, L.; Bruyneel, E.; Chastre, E.; Mareel, M.; Wymann, M. P; Gespach, C. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB. J., 2000, 14, 2329-2338.
153. Paik, S. S.; Jang, S. M.; Jang, K. S.; Lee, K. H.; Choi, D.; Jang, S. J. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann. Surg. Oncol, 2009, 16, 297-303.
154. Wang, D.; Chen, J.; Chen, H.; Duan, Z.; Xu, Q.; Wei, M.; Wang, L.; Zhong, M. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J. Biosci., 2012, 37, 91-101.
155. Ribatti, D.; Nico, B.; Belloni, A. S.; Vacca, A.; Roncali, L.; Nussdorfer, G. G. Angiogenic activity of leptin in the chick embryo chorioallantoic membrane is in part mediated by endogenous fibroblast growth factor-2. Int. J. Mol. Med., 2001, 8, 265-268.
156. Vona-Davis, L.; Rose, D. P. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev., 2009, 20, 193-201.
157. Gonzalez, R. R.; Cherfils, S.; Escobar, M.; Yoo, J. H.; Carino, C; Styer, A. K.; Sullivan, B. T; Sakamoto, H.; Olawaiye, A.; Serikawa, T.; Lynch, M. P.; Rueda, B. R. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J. Biol. Chem., 2006, 281, 26320-26328.
158. Uchiyama, T.; Takahashi, H.; Endo, H.; Sugiyama, M.; Sakai, E.; Hosono, K.; Nagashima, Y; Inayama, Y; Wada, K.; Hippo, Y; Nakajima, A. Role of the long form leptin receptor and of the STAT3 signaling pathway in colorectal cancer progression. Int. J. Oncol, 2011, 39, 935-940.
159. Steppan, CM.; Bailey, S. T.; Bhat, S.; Brown, E. J.; Banerjee, R. R.; Wright, CM.; Patel, H. R.; Ahima, R. S.; Lazar, M. A. The hormone resistin links obesity to diabetes. Nature, 2001, 409, 307-312.
160. Banerjee, R. R.; Lazar, M. A. Dimerization of resistin and resistin-like molecules is determined by a single cysteine. J. Biol. Chem., 2001, 276, 25970-25973.
161. Patel, S. D.; Rajala, M. W.; Rossetti, L.; Scherer, P. E.; Shapiro, L. Disulfidedependent multimeric assembly of resistin family hormones. Science, 2004, 304, 1154-1158.
162. Tiaka, E. K.; Manolakis, A. C.; Kapsoritakis, A. N.; Potamianos, S. P. The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev., 2011, 22, 109-119.
163. Steppan, CM.; Brown, E. J.; Wright, CM.; Bhat, S.; Banerjee, R. R.; Dai, C. Y; Enders, G. H.; Silberg, D. G.; Wen, X.; Wu, G. D. Lazar M. A. A family of tissue-specific resistin-like molecules. Proc. Natl. Acad. Sci. USA, 2001, 98, 502-506.
164. Zheng, L. D.; Tong, Q. S.; Weng, M. X.; He, J.; Lv, Q.; Pu, JR.; Jiang, G. S.; Cai, J. B.; Liu, Y; Hou, X. H. Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig. Dis. Sci., 2009, 54, 274-281.
165. Reaven, G. M. The insulin resistance syndrome: definition and dietary approaches to treatment. Annu. Rev. Nutr, 2005, 25, 391-406.
166. Komninou, D.; Ayonote, A.; Richie, J. P. Jr.; Rigas, B. Insulin resistance and its contribution to colon carcinogenesis. Exp. Biol. Med. (Maywood), 2003, 228, 396-405.
167. Wagner, K.; Hemminki, K.; Grzybowska, E.; Klaes, R.; Butkiewicz, D.; Pamula, J.; Pekala, W.; Zientek, H.; Mielzynska, D.; Siwinska, E.; Försti, A. The insulin-like growth factor-1 pathway mediator genes: SHC1 Met300Val shows a protective effect in breast cancer. Carcinogenesis, 2004, 25, 2473-2478.
168. Girnun, G. D.; Smith, W. M.; Drori, S.; Sarraf, P.; Mueller, E.; Eng, C; Nambiar, P.; Rosenberg, D. W.; Bronson, R. T.; Edelmann, W.; Kucherlapati, R.; Gonzalez, F. J.; Spiegelman, B. M. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc. Natl. Acad. Sci. U S A, 2002, 99, 13771-13776.
169. Balkwill, F; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357, 539-545.
170. Burnet, F. M. Immunological surveillance in neoplasia. Transplant. Rev, 1971, 7, 3-25.
171. Coussens, L. M.; Werb Z. Inflammation and cancer. Nature, 2002, 420, 860-867.
172. Aggarwal, B. B.; Gehlot, P. Inflammation and cancer: how friendly is the relationship for cancer patients? Curr. Opin. Pharmacol, 2009, 9, 351-369.
173. Itzkowitz, S. H. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin. North. Am., 2006, 35, 553-571.
174. Rizzo, A.; Pallone, F.; Monteleone, G.; Fantini, M. C. Intestinal inflammation and colorectal cancer: a double-edged sword? World J. Gastroenterol, 2011, 17, 3092-3100.
175. Szlosarek, P.; Balkwill, F. Tumour necrosis factor-α: A potential target in the therapy of solid tumors. Lancet Oncology, 2003, 4, 565-573.
176. Tisdale, M. J. Cancer cachexia. Langenbeck's Archive Surgery, 2004, 389, 299-305.
177. Mantovani, G.; Maccio, A.; Mura, L.; Serum levels of leptin and proinflammatory cytokines in patients with advanced stage cancer at different sites. J. Mol. Med,. 2000, 78, 554-561.
178. Ferroni, P.; Palmirotta, R.; Martini, F.; Ciatti, F.; Riondino, S.; Savonarola, A.; Spila, A.; Ciatti, F.; Sini, V; Mariotti, S.; Del Monte, G.; Roselli, M.; Guadagni, F. Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res., 2009, 29, 4131-4138.
179. Leek, RD.; Landers, R.; Fox, S. B.; Ng, F.; Harris, A. L.; Lewis, C. E. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br. J. Cancer, 1998, 77, 2246-2251.
180. Guadagni, F.; Ferroni, P.; Basili, S.; Facciolo, F.; Carlini, S.; Crecco, M.; Martini, F.; Spila, A.; Mineo, T. C.; Roselli, M. Correlation between Tumor Necrosis Factor-alpha and D-dimer Levels in Non-Small Cell Lung Cancer Patients. Lung Cancer, 2004, 44, 303-310.
181. Pfitzenmaier, J.; Vessella, R.; Higano, C. S.; Noteboom, J. L.; Wallace, D. Jr.; Corey, E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 2003, 97, 1211-1216.
182. Nakashima, J.; Tachibana, M.; Ueno, M.; Miyajima, A.; Baba, S.; Murai, M. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin. Cancer Res. 1998, 4, 1743-1748.
183. Ardizzoia, A.; Lissoni, P.; Brivio, F.; Tisi, E.; Perego, M. S.; Grassi, M. G.; Pittalis, S.; Crispino, S.; Barni, S.; Tancini, G. Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J. Biol. Regul. Homeost. Agents, 1992, 6, 103-107.
184. Yan, L.; Anderson, G. M.; De Witte, M.; Nakada, M. T. Therapeutic potential of cytokine and chemokines antagonists in cancer therapy. Eur. J. Cancer, 2006, 42, 793-802.
185. Roselli, M.; Guadagni, F.; Martini, F.; Spila, A.; Mariotti, S.; D'Alessandro, R.; Aloe, S.; Gazzaniga, P. P.; Basili, S.; Cosimelli, M.; Ferroni, P. Association between serum carcinoembryonic antigen and endothelial cell adhesion molecules in colorectal cancer. Oncology, 2003, 65, 132-138.
186. Guadagni, F.; Ferroni, P.; Palmirotta, R.; Portarena, I.; Formica, V; Roselli, M. TNF/VEGF cross-talking in chronic inflammation-related cancer initiation and progression: an early target in anticancer therapeutic strategy. In Vivo, 2007, 21, 147-162.
187. Belluco, C; Nitti, D.; Frantz, M.; Toppan, P.; Basso, D.; Plebani, M.; Lise, M.; Jessup, J. M. Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann. Surg. Oncol, 2000, 7, 133-138.
188. Ueda, T.; Shimada, E.; Urakawa, T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J. Gastroenterol. 1994, 29, 423-429.
189. Knüpfer, H.; Preiss, R.; Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int. J. Colorectal. Dis., 2010, 25, 135-140.
190. Aarons, C. B.; Bajenova, O.; Andrews, C; Heydrick, S.; Bushell K. N; Reed, K. L.; Thomas, P.; Becker, J. M.; Stucchi, A. F. Carcinoembryonic antigenstimulated THP-1 macrophages activate endothelial cells and increase cellcell adhesion of colorectal cancer cells. Clin. Exp. Metastasis, 2007, 24, 201-209.
191. Thomas, S. N.; Zhu, F.; Schnaar, R. L.; Alves, C. S.; Konstantopoulos, K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E-and L-selectin in shear flow. J. Biol. Chem., 2008, 283, 15647-15655.
192. Ferroni, P.; Roselli, M.; Spila, A.; D'Alessandro, R.; Portarena, I.; Mariotti, S.; Palmirotta, R.; Buonomo, O.; Petrella, G.; Guadagni, F. Serum sE-selectin levels and carcinoembryonic antigen mRNA-expressing cells in peripheral blood as prognostic factors in colorectal cancer patients. Cancer, 2010, 116, 2913-2921.
193. Il'yasova, D.; Colbert, LH.; Harris, TB.; Newman, AB.; Bauer, DC.; Satterfield, S.; Kritchevsky, S. B. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer. Epidemiol. Biomarkers. Prev. 2005, 14, 2413-2418.
194. Sharma, R.; Zucknick, M.; London, R.; Kacevska, M.; Liddle, C.; Clarke, SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin. Colorectal Cancer, 2008, 7, 331-337.
195. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med., 1999, 340, 448-454.
196. Erlinger, TP.; Platz, E. A.; Rifai, N.; Helzlsouer, K. J. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004, 291, 585-590.
197. Zhang, S. M.; Buring, J. E.; Lee, I. M.; Cook, N. R.; Ridker, P. M. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann. Intern. Med., 2005, 142, 425-432.
198. Ito, Y.; Suzuki, K.; Tamakoshi, K.; Wakai, K.; Kojima, M.; Ozasa, K.; Watanabe, Y.; Kawado, M.; Hashimoto, S.; Suzuki, S.; Tokudome, S.; Toyoshima, H.; Hayakawa, N.; Kato, K.; Watanabe, M.; Ohta, Y.; Maruta, M.; Tamakoshi, A.; JACC Study Group. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study. J. Epidemiol., 2005, 15, 185-189.
199. Otani, T.; Iwasaki, M.; Sasazuki, S.; Inoue, M.; Tsugane. S.; Japan Public Health Center-Based Prospective Study Group. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 690-695.
200. Gunter, M. J.; Stolzenberg-Solomon, R.; Cross, A. J.; Leitzmann, M. F.; Weinstein, S.; Wood, R. J.; Virtamo, J.; Taylor, P. R.; Albanes, D.; Sinha, R. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res., 2006, 66, 2483-2487.
201. Siemes, C.; Visser, L. E.; Coebergh, J. W.; Splinter, T. A.; Witteman, J. C.; Uitterlinden, A. G.; Hofman, A.; Pols, H. A.; Stricker, B. H. C-reactive protein levels. variation in the C-reactive protein gene. and cancer risk: the Rotterdam Study. J. Clin. Oncol., 2006, 24, 5216-5222.
202. Trichopoulos, D.; Psaltopoulou, T.; Orfanos, P.; Trichopoulou, A.; Boffetta, P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 381-384.
203. Allin, KH.; Bojesen S. E.; Nordestgaard, B. G. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 2009, 27, 2217-2224.
204. Aleksandrova, K.; Jenab, M.; Boeing, H.; Jansen, E.; Bueno-de-Mesquita, H. B.; Rinaldi, S.; Riboli, E.; Overvad, K.; Dahm, C. C.; Olsen, A.; Tjønneland, A.; Boutron-Ruault, M. C.; Clavel-Chapelon, F.; Morois, S.; Palli, D.; Krogh, V.; Tumino, R.; Vineis, P.; Panico, S.; Kaaks, R.; Rohrmann, S.; Trichopoulou, A.; Lagiou, P.; Trichopoulos, D.; van Duijnhoven, F. J.; Leufkens, A. M.; Peeters, P. H.; Rodríguez L.; Bonet, C.; Sánchez, M. J.; Dorronsoro, M.; Navarro, C.; Barricarte, A.; Palmqvist, R.; Hallmans, G.; Khaw, K. T.; Wareham, N.; Allen, N. E.; Spencer, E.; Romaguera, D.; Norat, T.; Pischon, T. Circulating C-Reactive Protein Concentrations and Risks of Colon and Rectal Cancer: A Nested Case-Control Study Within the European Prospective Investigation into Cancer and Nutrition. Am. J. Epidemiol., 2010, 172, 407-418.
205. Tsilidis, K. K.; Branchini, C.; Guallar, E.; Helzlsouer, K. J.; Erlinger, T. P.; Platz. E. A. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int. J. Cancer, 2008, 23, 1133-1140.
206. Pischon, T.; Lahmann, P. H.; Boeing, H.; Friedenreich, C.; Norat, T.; Tjønneland, A.; Halkjaer, J.; Overvad, K.; Clavel-Chapelon, F.; Boutron-Ruault, M. C.; Guernec, G.; Bergmann, M. M.; Linseisen, J.; Becker, N.; Trichopoulou, A.; Trichopoulos, D.; Sieri, S.; Palli, D.; Tumino, R.; Vineis, P.; Panico, S.; Peeters, PH.; Bueno-de-Mesquita, HB.; Boshuizen, H. C.; Van Guelpen, B.; Palmqvist, R.; Berglund, G.; Gonzalez, C. A.; Dorronsoro, M.; Barricarte, A.; Navarro, C.; Martinez, C.; Quirós, J. R.; Roddam, A.; Allen, N.; Bingham, S.; Khaw, KT.; Ferrari, P.; Kaaks, R.; Slimani, N.; Riboli, E. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J. Natl. Cancer. Inst., 2006, 98, 920-931.
207. Volkova, E.; Willis, J. A.; Wells, J. E.; Robinson, B. A.; Dachs, G. U.; Currie, MJ. Association of angiopoietin-2. C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br. J. Cancer., 2011, 104, 51-59.
208. Lee, S.; Choe, J. W.; Kim, H. K.; Sung, J. High-sensitivity C-reactive protein and cancer. J. Epidemiol., 2011, 21, 161-168.
209. Fujii, T.; Tabe, Y.; Yajima, R.; Yamaguchi, S.; Tsutsumi, S.; Asao T.; Kuwano, H. Elevated C-reactive protein level is associated with the tumor depth of invasion in patients with operable colorectal carcinoma. Hepatogastroenterology, 2011, 58, 1470-1473.
210. An, W.; Bai, Y.; Deng, S. X.; Gao, J.; Ben, Q. W.; Cai, Q. C.; Zhang, H. G.; Li, Z. S. Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur. J. Cancer Prev., 2012, 21, 126-133.
211. Schoen, R. E.; Tangen, CM.; Kuller, L. H.; Burke, G. L.; Cushman, M.; Tracy, R. P.; Dobs, A.; Savage, P. J. Increased blood glucose and insulin. body size. and indent colorectal cancer. J. Natl. Cancer Inst, 1999, 91, 1147-1154.
212. Giovannucci, E.; Aasherio, A.; Rimm, E. B.; Colditz, G. A.; Stampfer, M. J.; Willett, W. C. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann. Intern. Med., 1995, 122, 327-334.
213. Wei, E. K.; Giovannucci, E.; Fuchs, C. S.; Willett, W. C; Mantzoros, C. S. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J. Natl. Cancer Inst, 2005, 97, 1688-1694.
214. Otake, S.; Takeda, H.; Suzuki, Y.; Fukui, T.; Watanabe, S.; Ishihama, K.; Saito, T.; Togashi, H.; Nakamura, T.; Matsuzawa, Y.; Kawata S. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin. Cancer Res., 2005, 11, 3642-3646.
215. Ishikawa, M.; Kitayama, J.; Kazama, S.; Hiramatsu, T.; Hatano, K; Nagawa, H. Plasma adiponectin and gastric cancer. Clin. Cancer Res., 2005, 11, 466-472.
216. Ferroni, P.; Palmirotta, R.; Spila, A.; Martini, F.; Raparelli, V.; Fossile, E.; Mariotti, S.; Del Monte, G.; Buonomo, O.; Roselli, M.; Guadagni, F. Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res., 2007, 27, 483-490.
217. Gonullu, G.; Kahraman, H.; Bedir, A.; Bektas, A.; Yucel, I. Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int. J. Colorectal Dis., 2010, 25, 205-212.
218. Kemik, O.; Sumer, A.; Kemik, A. S.; Hasirci, I; Purisa, S.; Dulger, A. C.; Demiriz, B.; Tuzun, S. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J. Surg. Oncol, 2010, 8, 85.
219. Lukanova, A.; Soderberg, S.; Kaaks, R.; Jellum, E.; Stattin, P. Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 401-402.
220. Fukumoto, J.; Otake, T; Tajima, O.; Tabata, S.; Abe, H.; Mizoue, T; Ohnaka, K.; Kono, S. Adiponectin and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci., 2008, 99, 781-786.
221. Stocks, T.; Lukanova, A.; Johansson, M.; Rinaldi, S.; Palmqvist, R.; Hallmans, G.; Kaaks, R.; Stattin, P. Components of the metabolic syndrome and colorectal cancer risk: a prospective study. Int. J. Obes. (Lond.), 2008, 32, 304-314.
222. Wolf, I.; Sadetzki, S.; Kanety, H.; Kundel, Y; Pariente, C; Epstein, N.; Oberman, B.; Catane, R.; Kaufman, B.; Shimon, I. Adiponectin, ghrelin, and leptin in cancer cachexia in breast and colon cancer patients. Cancer, 2006, 106, 966-973.
223. Stattin, P.; Palmqvist, R.; Soderberg, S.; Biessy, C; Ardnor, B.; Hallmans, G.; Kaaks, R.; Olsson, T. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol. Rep., 2003, 10, 2015-2021.
224. Stattin, P.; Lukanova, A.; Biessy, C; Soderberg, S.; Palmqvist, R.; Kaaks, R.; Olsson, T; Jellum E. Obesity and colon cancer: does leptin provide a link? Int. J. Cancer, 2004, 109, 149-152.
225. Tamakoshi, K.; Toyoshima, H.; Wakai, K.; Kojima, M.; Suzuki, K.; Watanabe, Y; Hayakawa, N.; Yatsuya, H.; Kondo, T; Tokudome, S.; Hashimoto, S.; Suzuki, S.; Kawado, M.; Ozasa, K.; Ito, Y.; Tamakoshi, A. Leptin is associated with an increased female colorectal cancer risk: a nested casecontrol study in Japan. Oncology, 2005, 68, 454-461.
226. Tutino, V.; Notarnicola, M.; Guerra, V.; Lorusso, D.; Caruso, M. G. Increased soluble leptin receptor levels are associated with advanced tumor stage in colorectal cancer patients. Anticancer Res., 2011, 31, 3381-3383.
227. Healy, L. A.; Howard, J. M.; Ryan, A. M.; Beddy, P.; Mehigan, B.; Stephens, R.; Reynolds, J. V. Metabolic syndrome and leptin are associated with adverse pathological features in male colorectal cancer patients. Colorectal. Dis., 2012, 14, 157-165.
228. Wallace, A. M.; Sattar, N.; McMillan, D. C. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin. Cancer Res., 1998, 4, 2977-2979.
229. Bolukbas, F. F.; Kilic, H.; Bolukbas, C; Gumus, M.; Horoz, M.; Turhal, N. S.; Kavakli, B. Serum leptin concentration and advanced gastrointestinal cancers: a case controlled study. BMC Cancer, 2004, 4, 29.
230. Guadagni, F.; Roselli, M.; Martini, F.; Spila, A.; Riondino, S.; D'Alessandro, R.; Del Monte, G.; Formica, V.; Laudisi, A.; Portarena, I.; Palmirotta, R.; Ferroni, P. Prognostic Significance of Serum Adipokine Levels in Colorectal Cancer Patients. Anticancer Res., 2009, 29, 3321-3327.
231. Sǎlǎgeanu, A.; Tucureanu, C; Lerescu, L.; Caraş, I.; Pitica, R.; Gangurà, G.; Costea, R.; Neagu, S. Serum levels of adipokines resistin and leptin in patients with colon cancer. J. Med. Life, 2010, 3, 416-420.
232. Steppan, CM.; Lazar, M. A. The current biology of resistin. J. Int. Med., 2004, 255, 439-447.
233. Kumor, A.; Daniel, P.; Pietruczuk, M.; Malecka-Panas, E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int. J. Colorectal. Dis., 2009, 24, 275-281.
234. Nakajima, T. E.; Yamada, Y; Hamano, T; Furuta, K.; Matsuda, T; Fujita, S.; Kato, K.; Hamaguchi, T; Shimada, Y Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci., 2010, 101, 1286-1291.
235. Danese, E.; Montagnana, M.; Minicozzi, A. M.; Bonafini, S.; Ruzzenente, O.; Gelati, M.; De Manzoni, G.; Lippi, G.; Guidi, G. C. The role of resistin in colorectal cancer. Clin. Chim. Acta, 2012, 413, 760-764.
236. Janakiram, N. B.; Mohammed, A.; Rao, C. V. Role of lipoxins, resolvins, and other bioactive lipids in colon and pancreatic cancer. Cancer Metastasis Rev., 2011, 30, 507-523.
237. Wang, D.; Dubois, R. N. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene, 2010, 29, 781-788.
238. Guadagni, F.; Ferroni, P.; Palmirotta, R.; Del Monte, G.; Formica, V.; Roselli, M. Non-steroidal anti-inflammatory drugs in cancer prevention and therapy. Anticancer Res., 2007, 27, 3147-3162.
239. Bertagnolli, M. M. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol., 2007, 8, 439-443.
240. Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., Bolognese, J. A., Oxenius, B., Horgan, K., Loftus, S., Morton, D. G.; APPROVe Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 2006, 131, 1674-1682.
241. Arber, N., Eagle, C. J., Spicak, J., Rácz, I., Dite, P., Hajer, J., Zavoral, M., Lechuga, M. J., Gerletti, P., Tang, J., Rosenstein, R. B., Macdonald, K., Bhadra, P., Fowler, R., Wittes, J., Zauber, A. G., Solomon, S. D., Levin, B.; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med., 2006, 355, 885-895.
242. Kune, G. A. The Melbourne Colorectal Cancer Study: reflections on a 30-year experience. Med. J. Aust., 2010, 193, 648-652.
243. Ferrández, A., Piazuelo, E., Castells, A. Aspirin and the prevention of colorectal cancer. Best Pract. Res. Clin. Gastroenterol., 2012, 26, 185-195.
244. Rothwell, P. M.; Wilson, M.; Elwin, C. E.; Norrving, B.; Algra, A.; Warlow, C. P.; Meade, T. W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 2010, 376, 1741-1750.
245. Thun, M. J.; Jacobs, E. J.; Patrono, C. The role of aspirin in cancer prevention. Nat. Rev. Clin. Oncol., 2012, 9, 259-267.
246. Antithrombotic Trialists' (ATT) Collaboration; Baigent, C.; Blackwell, L.; Collins, R.; Emberson, J.; Godwin, J.; Peto, R.; Buring, J.; Hennekens, C.; Kearney, P.; Meade, T.; Patrono, C.; Roncaglioni, M. C.; Zanchetti, A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 2009, 373, 1849-1860.
247. Reddy, B. S.; Wang, C. X.; Maruyama, H. Effect of restricted caloric intake on azoxymethane-induced colon tumor incidence in male F344 rats. Cancer Res., 1987, 47, 1226-1228.
248. Raju, J.; Bird, R. P. Energy restriction reduces the number of advanced aberrant crypt foci and attenuates the expression of colonic transforming growth factor beta and cyclooxygenase isoforms in Zucker obese (fa/fa) rats. Cancer Res., 2003, 63, 6595-6601.
249. Pendyala, S.; Neff, L. M.; Suárez-Fariñas, M.; Holt, P. R. Diet-induced weight loss reduces colorectal inflammation: implications for colorectal carcinogenesis. Am. J. Clin. Nutr., 2011, 93, 234-242.
250. Byers, T.; Sedjo, R. L. Does intentional weight loss reduce cancer risk? Diabetes Obes. Metab., 2011, 13, 1063-1072.
251. Parker, E. D.; Folsom, A. R. Intentional weight loss and incidence of obesityrelated cancers: the Iowa Women's Health Study. Int. J. Obes. Relat. Metab. Disord., 2003, 27, 1447-1452.
252. Rapp, K.; Klenk, J.; Ulmer, H.; Concin, H.; Diem, G.; Oberaigner, W.; Schroeder, J. Weight change and cancer risk in a cohort of more than 65, 000 adults in Austria. Ann. Oncol., 2008, 19, 641-648.
253. Campbell, P. T.; Newton, C. C.; Dehal, A. N.; Jacobs, E. J.; Patel, A. V.; Gapstur, S. M. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J. Clin. Oncol., 2012, 30, 42-52.
254. García de la Torre, N.; Rubio, M. A.; Bordiú, E.; Cabrerizo, L.; Aparicio, E.; Hernández, C.; Sánchez-Pernaute, A.; Díez-Valladares, L.; Torres, A. J.; Puente, M.; Charro, A. L. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J. Clin. Endocrinol. Metab., 2008, 93, 4276-4281.
255. Sjöström, L.; Gummesson, A.; Sjöström, C. D.; Narbro, K.; Peltonen, M.; Wedel, H.; Bengtsson, C.; Bouchard, C.; Carlsson, B.; Dahlgren, S.; Jacobson, P.; Karason, K.; Karlsson, J.; Larsson, B.; Lindroos, A. K.; Lönroth, H.; Näslund, I.; Olbers, T.; Stenlöf, K.; Torgerson, J.; Carlsson, L. M.; Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol., 2009, 10, 653-662.
256. Adams, T. D.; Stroup, A. M.; Gress, R. E.; Adams, K. F.; Calle, E. E.; Smith, S. C.; Halverson, R. C.; Simper, S. C.; Hopkins, P. N.; Hunt, S. C. Cancer incidence and mortality after gastric bypass surgery. Obesity (Silver Spring), 2009, 17, 796-802.
257. Irwin, M. L. Physical activity interventions for cancer survivors. Br. J. Sports Med., 2009, 43, 32-38.
258. Jeon, J. Y.; Meyerhardt, J. A. Energy in and energy out: what matters for survivors of colorectal cancer? J. Clin. Oncol., 2012, 30, 7-10.
259. Gleeson, M.; Bishop, N. C.; Stensel, D. J.; Lindley, M. R.; Mastana, S. S.; Nimmo, M. A. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol., 2011, 11, 607-615.
260. Villareal, D. T.; Chode, S.; Parimi, N.; Sinacore, D. R.; Hilton, T.; Armamento-Villareal, R.; Napoli, N.; Qualls, C.; Shah, K. Weight loss, exercise, or both and physical function in obese older adults. N. Engl. J. Med., 2011, 364, 1218-1229.
261. Wolin, K. Y.; Yan, Y.; Colditz, G. A.; Lee, I. M. Physical activity and colon cancer prevention: a meta-analysis. Br. J. Cancer, 2009, 100, 611-616.
262. Meyerhardt, J. A.; Ma, J.; Courneya, K. S. Energetics in colorectal and prostate cancer. J. Clin. Oncol., 2010, 28, 4066-4073.
263. Courneya, K. S.; Booth, C. M.; Gill, S.; O'Brien, P.; Vardy, J.; Friedenreich, C. M.; Au, H. J.; Brundage, M. D.; Tu, D.; Dhillon, H.; Meyer, R. M. The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group. Curr. Oncol., 2008, 15, 279-285.
264. Morikawa, T.; Kuchiba, A.; Yamauchi, M.; Meyerhardt, J. A.; Shima, K.; Nosho, K.; Chan, A. T.; Giovannucci, E.; Fuchs, C. S.; Ogino, S. Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer. JAMA, 2011, 305, 1685-1694.
265. Johnson, I. T.; Lund, E. K. Review article: nutrition, obesity and colorectal cancer. Aliment. Pharmacol. Ther., 2007, 26, 161-181.
266. Bälter, K.; Möller, E.; Fondell, E. The effect of dietary guidelines on cancer risk and mortality. Curr. Opin. Oncol., 2012, 24, 90-102.
267. Shimizu, M.; Kubota, M.; Tanaka, T.; Moriwaki, H. Nutraceutical approach for preventing obesity-related colorectal and liver carcinogenesis. Int. J. Mol. Sci., 2012, 13, 579-595.
268. Pereira, F.; Larriba, M. J.; Muñoz, A. Vitamin D and colon cancer. Endocr. Relat. Cancer, 2012, 19, R51-71.
269. Roth, C. L.; Elfers, C. T.; Figlewicz, D. P.; Melhorn, S. J.; Morton, G. J.; Hoofnagle, A.; Yeh, M. M.; Nelson, J. E.; Kowdley, K. V. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology, 2012, 55, 1103-1111.
270. Lagunova, Z.; Porojnicu, A. C.; Grant, W. B.; Bruland, Ø.; Moan, J. E. Obesity and increased risk of cancer: does decrease of serum 25-hydroxyvitamin D level with increasing body mass index explain some of the association? Mol. Nutr. Food Res., 2010, 54, 1127-1133.
271. Hursel, R.; Viechtbauer, W.; Westerterp-Plantenga, M. S. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int. J. Obes. (Lond.), 2009, 33, 956-961.
272. Qin, B.; Polansky, M. M.; Harry, D.; Anderson, R. A. Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats. Mol. Nutr. Food Res., 2010, 54 Suppl 1, S14-23.
273. Yang, G.; Zheng, W.; Xiang, Y. B.; Gao, J.; Li, H. L.; Zhang, X.; Gao, Y. T.; Shu, X. O. Green tea consumption and colorectal cancer risk: a report from the Shanghai Men's Health Study. Carcinogenesis, 2011, 32, 1684-1688.
274. Stingl, J. C.; Ettrich, T.; Muche, R.; Wiedom, M.; Brockmöller, J.; Seeringer, A.; Seufferlein, T. Protocol for minimizing the risk of metachronous adenomas of the colorectum with green tea extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population. BMC Cancer, 2011, 11, 360.
275. Juan, M. E.; Alfaras, I.; Planas, J. M. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol. Res., 2012, 65, 584-591.
276. Rivera, L.; Morón, R.; Zarzuelo, A.; Galisteo, M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol., 2009, 77, 1053-1063.
277. Olholm, J.; Paulsen, S. K.; Cullberg, K. B.; Richelsen, B.; Pedersen, S. B. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int. J. Obes. (Lond.), 2010, 34, 1546-1553.
278. Vanamala, J.; Reddivari, L.; Radhakrishnan, S.; Tarver, C. Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer, 2010, 10, 238.
279. Friedenreich, C.; Norat, T.; Steindorf, K.; Boutron-Ruault, M. C.; Pischon, T.; Mazuir, M.; Clavel-Chapelon, F.; Linseisen, J.; Boeing, H.; Bergman, M.; Johnsen, N. F.; Tjønneland, A.; Overvad, K.; Mendez, M.; Quirós, J. R.; Martinez, C.; Dorronsoro, M.; Navarro, C.; Gurrea, A. B.; Bingham, S.; Khaw, K. T.; Allen, N.; Key, T.; Trichopoulou, A.; Trichopoulos, D.; Orfanou, N.; Krogh, V.; Palli, D.; Tumino, R.; Panico, S.; Vineis, P.; Bueno-de-Mesquita, H. B.; Peeters, P. H.; Monninkhof, E.; Berglund, G.; Manjer, J.; Ferrari, P.; Slimani, N.; Kaaks, R.; Riboli, E. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 2398-2407.
280. Mai, P. L.; Sullivan-Halley, J.; Ursin, G.; Stram, D. O.; Deapen, D.; Villaluna, D.; Horn-Ross, P. L.; Clarke, C. A.; Reynolds, P.; Ross, R. K.; West, D. W.; Anton-Culver, H.; Ziogas, A.; Bernstein, L. Physical activity and colon cancer risk among women in the California Teachers Study. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 517-525.
281. Meyerhardt, J. A.; Heseltine, D.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Thomas, J.; Nelson, H.; Whittom, R.; Hantel, A.; Schilsky, R. L.; Fuchs, C. S. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J. Clin. Oncol., 2006, 24, 3535-3541.
282. Haydon, A. M.; Macinnis, R. J.; English, D. R.; Giles, G. G. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut, 2006, 55, 62-67.
283. Meyerhardt, J. A.; Giovannucci, E. L.; Holmes, M. D.; Chan, A. T.; Chan, J. A.; Colditz, G. A.; Fuchs, C. S. Physical activity and survival after colorectal cancer diagnosis. J. Clin. Oncol., 2006, 24, 3527-3534.
284. Meyerhardt, J. A.; Giovannucci, E. L.; Ogino, S.; Kirkner, G. J.; Chan, A. T.; Willett, W.; Fuchs, C. S. Physical activity and male colorectal cancer survival. Arch. Intern. Med., 2009, 169, 2102-2108.